Psilocybin for treating substance use disorders?
This study (2017) reviews the human evidence regarding psilocybin as a potential treatment for substance use disorders (SUD). The authors conclude that the evidence thus far seems promising, but will need to be confirmed in future studies.
Authors
- Arnt Schellekens
Published
Abstract
Introduction: Evidence based treatment for Substance use disorders (SUD) includes psychotherapy and pharmacotherapy. However, these are only partially effective. Hallucinogens, such as psilocybin, may represent potential new treatment options for SUD. This review provides a summary of (human) studies on the putative therapeutic effects of psilocybin, and discusses the receptor systems, brain regions and cognitive and emotional processes mediating psilocybin’s effects. Psilocybin’s chemical structure is similar to that of serotonin. Dysregulations in the serotonin system are associated with alterations in stress hormones, such as cortisol, and mood disorders. After psilocybin administration cortisol levels spike and activate the executive control network, with subsequent increased control over emotional processes, and relief of negative thinking and persistent negative emotions. Preliminary data of ongoing alcohol and smoking addiction studies in humans shows promising effects of psilocybin administration on substance use. Importantly, psilocybin has a low risk of toxicity and dependence and can be used safely under controlled clinical conditions.Areas covered: This paper is a narrative review based on the search terms: psilocybin, substance use disorder, addiction, depression, serotonin. Literature on potential efficacy and mechanisms of action of psilocybin in SUD is discussed.Expert commentary: Recent positive findings with psilocybin need confirmation in well-designed placebo controlled randomized trials employing a large sample size.
Research Summary of 'Psilocybin for treating substance use disorders?'
Introduction
De Veen and colleagues frame substance use disorders (SUDs) as prevalent, chronic conditions with high relapse rates despite existing psychological and pharmacological treatments. The introduction emphasises that roughly 50-60% of patients with drug and alcohol use disorders relapse within 6–12 months after treatment and argues that novel interventions that reduce craving and substance use are urgently needed. The authors point to hallucinogens, in particular psilocybin, as a candidate treatment given recent promising findings and its pharmacological actions on serotonin systems implicated in emotion, stress and cognitive control. This narrative review aims to summarise human and relevant preclinical evidence for psilocybin’s therapeutic potential in SUD, and to discuss putative mechanisms of action through receptor systems, brain regions and cognitive and emotional processes. The authors set out to integrate clinical observations (including pilot studies in alcohol and tobacco dependence), neuropharmacology, neuroanatomy and network-level effects to generate hypotheses about how psilocybin might reduce addictive behaviour and inform directions for future research.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- Author
- APA Citation
de Veen, B. T., Schellekens, A. F., Verheij, M. M., & Homberg, J. R. (2017). Psilocybin for treating substance use disorders?. Expert Review of Neurotherapeutics, 17(2), 203-212. https://doi.org/10.1080/14737175.2016.1220834
References (17)
Papers cited by this study that are also in Blossom
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Gallimore, A. R. · Frontiers in Human Neuroscience (2015)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Hendricks, P. S., Clark, B., Johnson, M. W. et al. · Journal of Psychopharmacology (2014)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Show all 17 referencesShow fewer
Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)
Kraehenmann, R., Schmidt, A., Friston, K. et al. · NeuroImage (2015)
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Cited By (12)
Papers in Blossom that reference this study
Dallery, J., Miller, J. L., Boissoneault, J. et al. · Journal of Eating Disorders (2026)
Tap, S. C. · Addiction Biology (2024)
Rudin, D., Areesanan, A., Liechti, M. E. et al. · Frontiers in Psychiatry (2023)
Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V. et al. · Addiction Biology (2022)
O'shaughnessy, D. M., Sarnyai, Z., Quirk, F. et al. · SSM Qualitative Research in Health (2022)
Balaet, M. · Frontiers in Neuroscience (2022)
Maia, L. O., Massarentti, C. M., Tófoli, L.F. · Psychopharmacology (2022)
Yang, F., Yang, S., Tseng, P. et al. · Psychiatry Investigation (2021)
DiVito, A. J., Leger, R. F. · Molecular Biology Reports (2020)
Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)
Show all 12 papersShow fewer
Barsuglia, J. P., Polanco, M., Palmer, R. et al. · Progress in Brain Research (2018)
Dinis-Oliveira, R. J. · Drug Metabolism Reviews (2017)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.